Lantern Pharma Analyst Ratings
Lantern Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/15/2023 | 110.61% | EF Hutton | → $11 | Maintains | Buy |
| 11/01/2022 | 110.61% | EF Hutton | → $11 | Initiates Coverage On | → Buy |
| 03/11/2022 | 589.26% | HC Wainwright & Co. | $34 → $36 | Maintains | Buy |
| 11/02/2021 | 550.97% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/07/2021 | 512.67% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 07/28/2020 | 359.51% | Colliers Securities | → $24 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/15/2023 | 110.61% | EF Hutton | →$11 | 維護 | 買 |
| 11/01/2022 | 110.61% | EF Hutton | →$11 | 開始承保 | →購買 |
| 03/11/2022 | 589.26% | HC Wainwright公司 | $34→$36 | 維護 | 買 |
| 11/02/2021 | 550.97% | HC Wainwright公司 | $32→$34 | 維護 | 買 |
| 10/07/2021 | 512.67% | HC Wainwright公司 | →$32 | 開始承保 | →購買 |
| 07/28/2020 | 359.51% | 高力證券 | →$24 | 開始承保 | →購買 |
What is the target price for Lantern Pharma (LTRN)?
燈籠醫藥(LTRN)的目標價是多少？
The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by EF Hutton on February 15, 2023. The analyst firm set a price target for $11.00 expecting LTRN to rise to within 12 months (a possible 110.61% upside). 3 analyst firms have reported ratings in the last year.
燈籠製藥(納斯達克：LTRN)的最新目標價是由EF Hutton於2023年2月15日報道的。這家分析公司將目標價定為11美元，預計LTRN將在12個月內升至(可能上漲110.61%)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Lantern Pharma (LTRN)?
燈籠醫藥(LTRN)最新的分析師評級是多少？
The latest analyst rating for Lantern Pharma (NASDAQ: LTRN) was provided by EF Hutton, and Lantern Pharma maintained their buy rating.
英孚赫頓對花燈製藥(納斯達克代碼：LTRN)的最新分析師評級為買入，花燈製藥維持買入評級。
When is the next analyst rating going to be posted or updated for Lantern Pharma (LTRN)?
燈籠醫藥(LTRN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Lantern Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。對燈籠製藥的上一次評級是在2023年2月15日提交的，所以你應該預計下一次評級將在2024年2月15日左右的某個時候公佈。
Is the Analyst Rating Lantern Pharma (LTRN) correct?
分析師評級燈籠醫藥(LTRN)正確嗎？
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a maintained with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $5.22, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的燈籠製藥(LTRN)評級維持不變，目標價在0.00美元至11.00美元之間。Lantern Pharma(LTRN)目前的交易價格為5.22美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。